Amneal Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Chirag K. Patel
- Full Time Employees
- 8,500
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 400 Crossing Boulevard Bridgewater NJ United States of America 08807
- IPO Date
- May 7, 2018
- CIK
- 0001723128
- Website
- amneal.com
- Similar Companies
- Business
- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a global biopharmaceutical enterprise focused on enhancing health through the creation, production, and distribution of an extensive array of generic and specialized pharmaceutical products. Operating primarily within the United States, the company serves a broad spectrum of therapeutic areas and patient needs. The company's operations are strategically divided into three main segments: Affordable Medicines (previously Generics), Specialty, and AvKARE. The Affordable Medicines segment is dedicated to developing, manufacturing, and commercializing a diverse portfolio of generic drugs, including complex oral solids, sterile injectables, ophthalmics, liquids, topicals, biosimilars, and inhalation products. Amneal has been actively expanding its injectables portfolio, launching new products to address critical drug shortages, particularly in areas like oncology. This segment also includes the company's retail generics and international revenues. The Specialty segment concentrates on branded pharmaceutical products, primarily targeting central nervous system disorders, such as Parkinson's disease and migraine, and endocrine disorders like hypothyroidism. Key products in this division include Rytary for Parkinson's disease, Unithroid for hypothyroidism, and more recently launched products like Brekiya, an autoinjector for acute migraine and cluster headaches, and CREXONT for Parkinson's disease. Amneal aims to expand this portfolio through internal development, acquisitions, and strategic partnerships. The AvKARE segment functions as a distributor of pharmaceuticals, medical, and surgical products and services. It predominantly serves governmental agencies, including the Department of Defense and the Department of Veterans Affairs. AvKARE also engages in the wholesale distribution and packaging of bottle and unit-dose pharmaceuticals under its own labels, supplying both retail and institutional customers. Amneal acquired a majority interest in AvKARE in 2019 to bolster its presence in the federal healthcare market. Amneal distributes its products through a robust network that includes wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company maintains a global footprint with operations in the United States, India, Ireland, and other international markets. Founded in 2002 by Chirag and Chintu Patel, Amneal Pharmaceuticals, Inc. is headquartered in Bridgewater, New Jersey. The company became publicly traded in 2018 through a merger and continues to invest in research and development to bring new and complex medicines to market.
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock
Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
Amneal to Report Second Quarter 2026 Results on July 30, 2026
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations
Why Amneal Pharmaceuticals (AMRX) is a Top Momentum Stock for the Long-Term
The Healthcare M&A Wave
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?
Is Amneal Pharmaceuticals Inc (AMRX) Overvalued After 4.4% Rally? GF Value Says Overvalued
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase
Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Amneal and Pfizer GLP-1 Deal: New Growth Lever?
Is Amneal a Buy Before Rytary Generic Erosion?
What's Driving Amneal's 2026 Growth Outlook?
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock
Amneal Stock Up on FDA Nod for Romidepsin Injection Solution
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
Amneal Pharmaceuticals gets FDA approval for romidepsin injection solution